A Genetic Association Study of MTHFR C677T Polymorphism with Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis

  • Soheil Azizi 1. Department of Laboratory Sciences, Faculty of Paramedicine, Mazandaran University of Medical Sciences, Sari, Iran
  • Amir Shamshirian 2. Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
  • Reza Alizadeh-Navaei 3. Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran
  • Hamed Jafarpour 2. Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
  • Zatollah Asemi 4. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of MedicalSciences, Kashan, Iran
  • Omid Reza Tamtaji 5. Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran
  • Mohammad Sadegh Vaziri 6. Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
  • Reza Homayounfar 7. Non-Communicable Disease Research Center, Fasa University of Medical Sciences, Fasa, Iran
  • Arash Rezaei Shahmirzadi 8. Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
  • Reza Alipoor 6. Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran 7. Non-Communicable Disease Center, Fasa University of Medical Sciences, Fasa, Iran
Keywords: MTHFR; Metabolic Syndrome; Polymorphism; Variant; Meta-Analysis; Methylenetetrahydrofolate Reductase


Methylenetetrahydrofolate reductase (MTHFR) is an enzyme that plays a crucial role as a methyl-group donor in demethylation of homocysteine. The aim of this systematic review and meta-analysis was to study the relationship between MTHFR gene polymorphism and metabolic syndrome (MS). We used search engines and databases such as Science Direct, Google Scholar, Embase, Cochrane Library, and PubMed to identify eligible studies up to 2018. The articles were studied based on keywords including MTHFR, mutation, variant, and polymorphism in combination with MS. Data was analyzed using Comprehensive Meta-Analysis version 2.2.064 software. After extracting the data from seven articles, the total number of subjects was 1280 in the patient group and 1374 in the control group. The odds ratio was estimated to be 1.078 for the allele model of T vs. C (95% confidence interval [CI]: 1.626-0.715), 1.157 for the allele model of CC vs. CT (95% CI: 0.829-1.615), 1.020 for the allele model of CT + TT vs. CC (95% CI: 1.611-0.646) and 0.799 for the allele model of TT vs. CC + CT (95% CI: 1.185-0.539). As well, the results showed no statistically significant correlation between polymorphism genotypes of the MTHFR gene and MS (P<0.05). In general, this study showed that the presence of C677T polymorphism in the MTHFR gene has no effect on the incidence of MS. [GMJ.2019;8:e1472]


Maroto-Sánchez B, Lopez-Torres O, Palacios G, González-Gross M. What do we know about homocysteine and exercise? A review from the literature.

Clin Chem Lab Med. 2016;54(10):1561-77.

Frosst P, Blom H, Milos R, Goyette P, Sheppard CA, Matthews R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111-3.



Outinen PA, Patricia C, SARGE KD, MAEDA N, HIRSH J, RIBAU J, et al. Characterization of the stress-inducing effects of homocysteine. Biochem J. 1998;332(1):213-21.


PMid:9576870 PMCid:PMC1219470

van Guldener C, Stehouwer CD, editors. Diabetes mellitus and hyperhomocysteinemia. Seminars in vascular medicine; 2002: Copyright© 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Becker A, Smulders Y, Van Guldener C, Stehouwer C. Epidemiology of homocysteine as a risk factor in diabetes. Metab Syndr Relat Disord. 2003;1(2):105-20.



Li S, Zhu J, Wu L, Peng L, Luo Y, Zhao Y, et al. The association between plasma homocysteine and ambulatory blood pressure variability in patients with untreated hypertension. Clin Chim Acta. 2018;477:32-8.



Cai W, Yin L, Yang F, Zhang L, Cheng J. Association between Hcy levels and the CBS844ins68 and MTHFR C677T polymorphisms with essential hypertension. Biomed Rep. 2014;2(6):861-8.


PMid:25279160 PMCid:PMC4179705

Martos R, Valle M, Morales R, Cañete R, Gavilan MI, Sánchez-Margalet V. Hyperhomocysteinemia correlates with insulin resistance and low-grade systemic inflammation in obese prepubertal children. Metabolism. 2006;55(1):72-7.



Lenna S, Han R, Trojanowska M. Endoplasmic reticulum stress and endothelial dysfunction. IUBMB life. 2014;66(8):530-7.


PMid:25130181 PMCid:PMC4181710

Giltay E, Hoogeveen E, Elbers J, Gooren L, Asscheman H, Stehouwer C. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis. 1998;139(1):197-8.

Ghogomu S, Ngolle N, Mouliom R, Asa B. Association between the MTHFR C677T gene polymorphism and essential hypertension in South West Cameroon. Genet Mol Res. 2016;15(1):28.



Zhu B, Wu X, Zhi X, Liu L, Zheng Q, Sun G. Methylenetetrahydrofolate reductase C677T polymorphism and type 2 diabetes mellitus in Chinese population: a meta-analysis of 29 case-control studies. PloS one. 2014;9(7):e102443.


PMid:25047451 PMCid:PMC4105552

Liew S-C, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet. 2015;58(1):1-10.



Wu S, Han Y, Hu Q, Zhang X, Cui G, Li Z, et al. Effects of common polymorphisms in the MTHFR and ACE genes on diabetic peripheral neuropathy progression: a meta-analysis. Mol Neurobiol. 2017;54(4):2435-44.



Russo G, Di Benedetto A, Alessi E, Ientile R, Antico A, Nicocia G, et al. Mild hyperhomocysteinemia and the common C677T polymorphism of methylene tetrahydrofolate reductase gene are not associated with the metabolic syndrome in Type 2 diabetes. J Endocrinol Invest. 2006;29(3):201-7.



Roffeei SN, Mohamed Z, Reynolds GP, Said MA, Hatim A, Mohamed EHM, et al. Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. Pharmacogenomics. 2014;15(4):477-85.



Tang R, Liu H, Yuan Y, Xie K, Xu P, Liu X, et al. Genetic factors associated with risk of metabolic syndrome and hepatocellular carcinoma. Oncotarget. 2017;8(21):35403.


PMid:28515345 PMCid:PMC5471064

Chedraui P, Pérez-López F, Escobar G, Espinoza-Caicedo J, Montt-Guevara M, Genazzani A, et al. Polymorphisms of the FTO and MTHFR genes and vascular, inflammatory and metabolic marker levels in postmenopausal women. J Endocrinol Invest. 2016;39(8):885-90.



Chen A-R, Zhang H-G, Wang Z-P, Fu S-J, Yang P-Q, Ren J-G, et al. C-reactive protein, vitamin B12 and C677T polymorphism of N-5, 10-methylenetetrahydrofolate reductase gene are related to insulin resistance and risk factors for metabolic syndrome in Chinese population. Clin Invest Med. 2010;33(5):290-7.


Fakhrzadeh H, Tavakoli J, Amoli M, Mirarefin M, Sharifi F, Ghotbi S, et al. Investigation of the Relation of Methylenetetrahydrofolic Acid MTHFR (C677T) Reduction Gene with Metabolic Syndrome in the Iranian Population: Tehran Homocysteine Study. ijdld. 2009;8(3):289-98.

Kang BS, Ahn DH, Kim NK, Kim JW. Relationship between metabolic syndrome and MTHFR polymorphism in colorectal cancer. J Korean Soc Coloproctol. 2011;27(2):78-82.


PMid:21602966 PMCid:PMC3092079

Yang B, Fan S, Zhi X, Wang D, Li Y, Wang Y, et al. Associations of MTHFR C677T and MTRR A66G gene polymorphisms with metabolic syndrome: a case-control study in Northern China. Int J Mol Sci. 2014;15(12):21687-702.


PMid:25429430 PMCid:PMC4284672

Zeman M, Jáachymová M, Jirák R, Vecka M, Tvrzická E, Stankova B, g. Polymorphisms of genes for brain-derived neurotrophic factor, methylenetetrahydrofolate reductase, tyrosine hydroxylase, and endothelial nitric oxide synthase in depression and metabolic syndrome. Folia Biol. 2010;56(1):19.

Yamada Y, Kato K, Hibino T, Yokoi K, Matsuo H, Segawa T, Watanabe S, Ichihara S, Yoshida H, Satoh K, Nozawa Y. Prediction of genetic risk for metabolic syndrome. Atherosclerosis. 2007 Apr 1;191(2):298-304.



Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res. 2008;98(1):47-54.


PMid:17976958 PMCid:PMC2271139

Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic syndrome. Diabetes. 2005;54(7):1899-906.



Lu Q, Qiu X, Hu N, Wen H, Su Y, Richardson B. Epigenetics, disease, and therapeutic interventions. Ageing Res Rev. 2006;5(4):449-67.



Waterland RA, Jirtle RL. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition. 2004;20(1):63-8.


How to Cite
Azizi, S., Shamshirian, A., Alizadeh-Navaei, R., Jafarpour, H., Asemi, Z., Tamtaji, O. R., Vaziri, M. S., Homayounfar, R., Rezaei Shahmirzadi, A., & Alipoor, R. (2019). A Genetic Association Study of MTHFR C677T Polymorphism with Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis. Galen Medical Journal, 8, e1472. https://doi.org/10.31661/gmj.v8i0.1472
Review Article